Endo pain drug flunks a Ph2 test

A little more than two years after in-licensing a pain drug from Grunenthal, Endo Pharmaceuticals said today that the treatment failed a mid-stage, placebo-controlled study for lower back pain. Endo said it would complete its analysis of the data on axomadol and then decide how it would proceed with the program. Endo release

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.